查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1825313

乳糜泻治疗市场：2025-2030 年预测

Celiac Disease Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计乳糜泻治疗市场将从 2025 年的 5.0182 亿美元成长到 2030 年的 9.61137 亿美元，复合年增长率为 13.88%。

乳糜泻治疗市场是消化器官系统和自体免疫疾病治疗行业中一个独特的细分市场。乳糜泻是一种自体免疫疾病，由消化器官系统引起的小肠损伤引起，损害了脂肪、钙、铁和叶酸等必需营养素的吸收。这种遗传性疾病与家族病史密切相关，例如第1型糖尿病、自体免疫甲状腺疾病、唐氏症、类风湿性关节炎、显微镜下结肠炎和爱迪生氏症。

病理生理学和市场基础

乳糜泻是一种自体免疫疾病，其独特的治疗环境使传统药物疗法面临巨大挑战。由于其遗传基础和复杂的免疫反应机制，麸质暴露会损害小肠粘膜，因此需要一种超越传统药物疗法的综合治疗方法。

市场既需要解决即时症状缓解，也需要解决患者长期营养吸收问题，而这正是患者体验的关键。这种双重治疗需求为多样化的治疗方式和全面的护理解决方案创造了机会。

市场成长的关键驱动力

抗发炎药物和治疗性疫苗的开发是变革的驱动力，为严格的无麸质饮食提供了潜在的替代方案。这些创新的治疗方法解决了潜在的免疫反应机制，并为超越现有饮食策略的更全面的疾病管理提供了机会。

医疗保健支出的增加和医学研究投入的增加为市场扩张创造了有利条件。加强乳糜泻临床试验和药物研发的资金投入，将加速潜在治疗方法的研发，并透过技术创新和扩大治疗方案来推动市场成长。

医疗机构的医疗保健宣导活动透过提高疾病认知度和诊断率，显着促进了市场成长。教育宣传活动和专业培训计画有望加深人们对乳糜泻症状和诊断方法的理解，从而降低当前市场普遍存在的漏诊率。

糖尿病盛行率的上升是关键的成长动力，因为糖尿病患者更容易患上乳糜泻。这种相关性导致越来越多的患者需要同时治疗两种疾病的专门治疗方法，从而推动了对综合治疗解决方案的需求。

饮食趋势转向加工食品、速食和即食包装产品，导致一般人群麸质摄取量增加。生活方式的改变、都市化和可支配收入的增加，这些因素共同导致了饮食模式的改变，从而可能增加乳糜泻的盛行率，从而为治疗方案创造了持续的市场需求。

地理市场分布

欧洲和北美是最大的区域市场，得益于高发病率和完善的医疗基础设施。这些地区拥有先进的诊断能力、全面的医疗保健和强大的研发生态系统，为市场发展提供支援。

由于某些人群（尤其是撒哈拉人口）的盛行率较高，非洲拥有巨大的市场潜力，然而，有限的医疗基础设施和诊断能力可能会影响这些地区的市场发展。

市场限制和治疗挑战

乳糜泻特效治疗方法的匮乏是市场发展的根本限制因素。缺乏能够直接作用于自体免疫反应机制的标靶药物疗法，迫使人们必须依赖饮食管理，限制了治疗方案的选择和市场拓展潜力。

漏诊和误诊率高是主要的市场障碍。由于症状多变、诊断复杂、医护人员认知度低，许多乳糜泻病例仍未确诊，导致大量患者未治疗，因此无法满足市场需求。

竞争格局与创新

市场上，既有像 General Mills, Inc. 和 Glenmark Pharmaceuticals Inc. 这样的老牌药厂，也有像 BioLineRx 这样的新兴企业进入治疗开发领域。这种竞争态势正透过伙伴关係、创新解决方案的开发以及以患者为中心的治疗方法推动创新。

我们的策略性倡议致力于提升患者的舒适度和治疗依从性，同时拓展传统无麸质饮食管理以外的治疗选择。我们专注于兼顾症状管理和生活品质的创新解决方案，为市场差异化和成长创造机会。

对战略产业的影响

对于医疗保健专业人士而言，乳糜泻治疗市场代表着自体免疫疗法、营养医学和个人化治疗方法交叉融合的机会。为了取得成功，他们必须应对诊断挑战，同时开发超越当前饮食限制模式的创新治疗方案。

本报告的主要优点

  • 深刻分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场。
  • 竞争格局：了解主要企业所采用的策略策略，并了解正确策略的市场渗透潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力来制定策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业来说，既有利又划算。

它有什么用途？

产业与市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2022 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测细分市场和区域分析（包括国家）
  • 公司概况（尤其是财务状况和关键发展）

目录

第一章执行摘要

第二章市场概述

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

5. 乳糜泻治疗市场（按类型）

  • 介绍
  • 维生素和营养补充剂
  • 类固醇
  • 免疫抑制剂
  • 治疗性疫苗
  • 酵素疗法
  • 无麸质饮食产品
  • 生物製药

6. 依给药途径分類的乳糜泻治疗市场

  • 介绍
  • 口服
  • 注射

7. 乳糜泻治疗市场（依通路）

  • 介绍
  • 医院药房
  • 零售药局
  • 网路药局

第八章 乳糜泻治疗市场：按地区

  • 介绍
  • 北美洲
    • 按类型
    • 依给药途径
    • 按分销管道
    • 按国家
      • 美国
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按类型
    • 依给药途径
    • 按分销管道
    • 按国家
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 按类型
    • 依给药途径
    • 按分销管道
    • 按国家
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 按类型
    • 依给药途径
    • 按分销管道
    • 按国家
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 按类型
    • 依给药途径
    • 按分销管道
    • 按国家
      • 中国
      • 日本
      • 印度
      • 韩国
      • 台湾
      • 其他的

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章：公司简介

  • Innovate Biopharmaceuticals Inc.
  • BioLineRx Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • Glutenostics LLC

第十一章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061610419

The Celiac Disease Treatment Market is expected to grow from USD 501.820 million in 2025 to USD 961.137 million in 2030, at a CAGR of 13.88%.

The celiac disease treatment market represents a specialized segment within the gastrointestinal and autoimmune disorder therapeutics industry. Celiac disease is characterized as a digestive autoimmune disorder that impairs the body's ability to absorb essential nutrients including fat, calcium, iron, and folate due to small intestine damage caused by gluten consumption. This gene-based inherited condition demonstrates strong correlations with family histories of type 1 diabetes, autoimmune thyroid disorders, Down syndrome, rheumatoid arthritis, microscopic colitis, and Addison's disease.

Disease Pathophysiology and Market Foundation

The autoimmune nature of celiac disease creates a unique therapeutic landscape where traditional pharmaceutical interventions face significant challenges. The condition's genetic basis and complex immune response mechanisms result in damaged small intestine lining upon gluten exposure, necessitating comprehensive treatment approaches that extend beyond conventional drug therapies.

The market's foundation rests on addressing both immediate symptom management and long-term nutritional absorption issues that define the patient experience. This dual therapeutic requirement creates opportunities for diverse treatment modalities and comprehensive care solutions.

Primary Market Growth Drivers

The development of anti-inflammatory drugs and therapeutic vaccines represents a transformative growth driver, offering potential alternatives to strict gluten-free dietary restrictions. These innovative therapeutic approaches address the underlying immune response mechanisms, providing opportunities for more comprehensive disease management beyond current dietary limitation strategies.

Rising healthcare expenditure and increased investment in medical research create favorable conditions for market expansion. Enhanced funding for clinical trials and drug development specifically targeting celiac disease accelerates the pipeline of potential therapeutic solutions, driving market growth through innovation and expanded treatment options.

Healthcare awareness initiatives by medical organizations contribute significantly to market growth through improved disease recognition and diagnosis rates. Educational campaigns and professional training programs enhance understanding of celiac disease symptoms and diagnostic approaches, potentially reducing underdiagnosis rates that currently characterize the market.

The rising prevalence of diabetes represents a critical growth catalyst, as diabetic patients demonstrate increased susceptibility to celiac disease development. This correlation creates expanded patient populations requiring specialized treatment approaches that address both conditions simultaneously, driving demand for integrated therapeutic solutions.

Dietary trend shifts toward processed foods, fast food consumption, and ready-to-eat packaged products increase gluten exposure in general populations. Lifestyle changes, urbanization, and rising disposable income contribute to dietary patterns that may increase celiac disease prevalence, creating sustained market demand for treatment solutions.

Geographic Market Distribution

Europe and North America represent the largest regional markets, supported by high disease prevalence rates and well-established healthcare infrastructure. These regions benefit from advanced diagnostic capabilities, comprehensive healthcare coverage, and robust research and development ecosystems that support market growth.

Africa presents significant market potential, particularly given the high prevalence rates observed in certain populations, such as the Saharawi people. However, healthcare infrastructure limitations and diagnostic capacity constraints may impact market development in these regions.

Market Constraints and Treatment Challenges

The limited availability of specific pharmaceutical treatments for celiac disease represents a fundamental market constraint. The absence of targeted drug therapies that directly address the autoimmune response mechanisms forces reliance on dietary management approaches, limiting therapeutic options and market expansion potential.

Significant underdiagnosis and misdiagnosis rates create substantial market barriers. Many celiac disease cases remain unidentified due to symptom variability, diagnostic complexity, and limited healthcare provider awareness, resulting in untreated patient populations that do not contribute to market demand.

Competitive Landscape and Innovation

The market features established pharmaceutical companies including General Mills, Inc. and Glenmark Pharmaceuticals Inc., alongside emerging players like BioLineRx entering the therapeutic development space. This competitive dynamic drives innovation through partnerships, novel solution development, and patient-focused treatment approaches.

Strategic initiatives focus on enhancing patient comfort and treatment adherence while expanding therapeutic options beyond traditional gluten-free dietary management. The emphasis on innovative solutions that address both symptom management and quality of life considerations creates opportunities for market differentiation and growth.

Strategic Industry Implications

For healthcare industry professionals, the celiac disease treatment market represents opportunities at the intersection of autoimmune therapeutics, nutritional medicine, and personalized treatment approaches. Success requires addressing diagnostic challenges while developing innovative therapeutic solutions that extend beyond current dietary restriction paradigms.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Celiac Disease Treatment Market Segmentation:

By Type

  • Vitamins and Dietary Supplements
  • Steroids
  • Immunosuppressive Drugs
  • Therapeutic Vaccines
  • Enzyme Therapy
  • Gluten-Free Diet Products
  • Biologics

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CELIAC DISEASE TREATMENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Vitamins and Dietary Supplements
  • 5.3. Steroids
  • 5.4. Immunosuppressive Drugs
  • 5.5. Therapeutic Vaccines
  • 5.6. Enzyme Therapy
  • 5.7. Gluten-Free Diet Products
  • 5.8. Biologics

6. CELIAC DISEASE TREATMENT MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Injectable

7. CELIAC DISEASE TREATMENT MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Retail Pharmacies
  • 7.4. Online Pharmacies

8. CELIAC DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Route of Administration
    • 8.3.3. By Distribution Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Route of Administration
    • 8.4.3. By Distribution Channel
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Route of Administration
    • 8.5.3. By Distribution Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Route of Administration
    • 8.6.3. By Distribution Channel
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Taiwan
      • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Innovate Biopharmaceuticals Inc.
  • 10.2. BioLineRx Ltd.
  • 10.3. Takeda Pharmaceutical Company Ltd.
  • 10.4. Glutenostics LLC

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key benefits for the stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations